*BAYER-15786




A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS).
Rivaroxaban
15786
NCT01776424
MACE prevention
Phase 3
 
Since study is still ongoing, data provided will be on basis of datasets provided to authorities for obtaining market approval.
April 2019